GSK files for European approval of gene therapy
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has filed for approval to market a gene therapy in Europe. GSK2696273, developed with Italian scientists from Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR), is for the treatment of the ultra-rare disease adenosine deaminase severe combined immunodeficiency syndrome (ADA-SCID) in patients for whom a suitable bone marrow donor cannot be found.